Arrowhead Pharmaceuticals released interim Phase 1/2 data showing its RNAi candidate ARO-INHBE, given with Lilly’s tirzepatide (Zepbound), produced larger reductions in weight, visceral fat and liver fat than tirzepatide alone in a small cohort of patients with obesity and diabetes. In the dataset reported, combination patients lost roughly 9.4% body weight vs. 4.8% on tirzepatide alone at 16 weeks; reductions in visceral and liver fat were markedly greater in the combination arm. Arrowhead characterized the results as encouraging early signals that gene‑silencing therapies could augment incretin-based weight loss, while cautioning that findings are preliminary and from a limited number of participants. The readout adds to competition in longer‑acting and combination obesity approaches and may accelerate interest in RNAi programs paired with GLP-1/GIP receptor agonists.